Compare the endometrium of oocyte donors, who had final oocyte maturation with either hCG, Suprefact, followed by hCG 35 hours after triggering, Suprefact or Suprefact without luteal phase support. Group A, B, C receive luteal phase support for 5 days, until the day of endometrial sampling (OPU+5). To avoid inter-patient variation in endometrial histology, each patient will preferably perform 4 consecutive oocyte donation cycles, within one year, using models A-D for final oocyte maturation
Conditions
Interventions
Trade Name: Pregnyl 1500 IU
Product Name: Pregnyl 1500 IU
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: choriongonadotrofine (hCG)
Concentration unit: IU inte
Sponsors
FREE UNIVERSITY OF BRUSSELS
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • All patients qualifying as oocyte donors i.e. • A minimum of 5-10 antral follicles in each ovary • Normal genetic analysis • Normal caryotype • Normal serological findings within 3 months prior to stimulation • Normal vaginal ultrasound • No IUD Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • PCOS (Rotterdam criteria) • Age = 36 years • BMI = 30 • Severe endometriosis • Hydrosalpinges, visible at ultrasound
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: comparison of endometrial status after different types of final oocyte maturation;Secondary Objective: ;Primary end point(s): Study groups A, B, C and D: Histological markers (Noyes criteria) in all samples as well as gene expression in a subset of each group. A set of classical implantation markers can be added, ie osteopontin, glycodelinA, Dickkopf, transcobalamin, dipeptidilpeptidase IV. Differentially expressed genes in the three groups can be further explored and compared to already known implantation factors. Progesterone-receptor, LH-receptor expression and oestradiol-receptor expression, possibly performed with quantitative RT-PCR in relation to two or three house-hold genes constantly expressed. Further analysis of gene expression with the Affymetrix HGU133Plus2 microarray. According to previous publications, the significantly up and down regulated genes will be analysed (SERPINB6, FOXO3A, SOX17, and CDC42, NRP1, HOXA10, and OSF2). | — |
Countries
Belgium
Outcome results
None listed